Curriculum vitae matthew ryan weir, M. D



Download 0.51 Mb.
Page1/7
Date conversion04.02.2017
Size0.51 Mb.
  1   2   3   4   5   6   7

CURRICULUM VITAE
MATTHEW RYAN WEIR, M.D.

Professor and Director

Division of Nephrology

University of Maryland School of Medicine


Date February 3, 2017

Contact Information


Matthew R. Weir, M.D.

Professor and Director

Division of Nephrology

University of Maryland Medical Center

22 S. Greene Street, Room N3W143

Baltimore, Maryland 21201

Phone: 410.328.5720

Fax: 410.328.5685

Email: mweir@medicine.umaryland.edu
Education

1974 B.A. University of Virginia

Charlottesville, Virginia
1978 M.D. University of Virginia

Charlottesville, Virginia


Internship

1978-1979 The Waterbury Hospital and Yale-New Haven Hospital

Yale University School of Medicine

New Haven, CT


Residency

1979-1980 Junior Assistant Resident in Medicine, The Waterbury Hospital and Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT


1980-1981 Senior Assistant Resident in Medicine, The Waterbury Hospital and Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT
Research Fellowships:

1981-1982 Clinical Nephrology Fellow, Harvard Medical School and The Brigham and Women's Hospital, Boston, MA


1982-1983 Laboratory of Immunogenetics and Transplantation, Renal Division, Harvard Medical School and The Brigham and Women's Hospital, Boston, MA
POSTGRADUATE CLINICAL EXPERIENCE
1981-1983 General Practice Clinic

The Brigham and Women's Hospital

Boston MA
1981-1983 Medical Consultant

Parker Hill Hospital

Boston, MA

1981-1983 Medical Consultant, Intensive Care Unit

Marlborough Hospital

Marlborough, MA


1983-Present Attending Physician

University of Maryland Hospital,

Baltimore, MD

LICENSURE AND CERTIFICATION

1979 Diplomate of the National Board of Medical Examiners

1980 Connecticut License Registration

1981 Massachusetts License Registration

1981 Diplomate of the American Board of Internal Medicine

1983 Maryland License Registration (#D29710)

1984 Diplomate of the American Board of Internal Medicine for the Subspecialty of Nephrology
MAJOR RESEARCH INTERESTS
▪ Immunobiology of tolerance in allograft transplantation

▪ Hypertensive nephropathy in blacks

▪ Hypertension - Impact of antihypertensive agents on renal hemodynamics, end-organ protection, and modulation of renal-adrenal responses

▪ The influence of dietary sodium on insulin sensitivity, blood pressure, renal hemodynamics and proteinuria in

hypertensive patients

▪ Mechanisms and treatment of allograft nephropathy

▪ Cardiovascular disease associated with chronic kidney disease
FACULTY POSITIONS
1983-1989 Assistant Professor of Medicine

University of Maryland School of Medicine

Baltimore, MD

1989-1994 Associate Professor of Medicine

University of Maryland School of Medicine

Baltimore, MD


1994-Present Professor of Medicine

University of Maryland School of Medicine

Baltimore, MD
1994-Present Director, Division of Nephrology

University of Maryland School of Medicine

Baltimore, MD
MAJOR ACADEMIC TASKS
1983-1990 Medical Director, Transplantation Service

University of Maryland Hospital

Baltimore, MD
1983-1990 Medical Director, Transplantation Clinic

University of Maryland Hospital

Baltimore, MD

1986-Present Task Force on Hypertensive Emergencies

University of Maryland Hospital

Baltimore, MD


1988-Present Medical Director, Clinical Research Unit

University of Maryland Hospital

Baltimore, MD
1990-Present Director, Nephrology Fellowship Training Program

University of Maryland Hospital

Baltimore, MD
1991-Present Associate Director, Organ Transplantation Services

University of Maryland Hospital

Baltimore, MD

PROFESSIONAL MEMBERSHIPS
1980 Member, American College of Physicians

1982 Member, International Society of Nephrology

1983 Member, American Federation of Clinical Research

1984 Member, American Society of Nephrology

1984 Member, Baltimore City Medical Society

1984 Member, Medical & Chirurgical Faculty of Maryland

1985 Member, The Transplantation Society

1986 Member, American Society of Transplant Physicians

1986 Member, National Kidney Foundation

1986 Member, Renal Physicians Association

1987-88 Co-Director, Program Committee of the Third International

Interscience Conference on Hypertension in Blacks.

1988 Member, American Society of Hypertension

1988 Fellow, American College of Physicians

1988-91 Member, Scientific Review Committee, American Society of Transplant Physicians

1991-Present Reviewer of Abstracts for American Society of Transplantation Meeting

1992,1995,1997-present Reviewer of Abstracts for American Society of Nephrology

1993-1997 Member, Kidney-Pancreas Committee, American Society of Transplant Physicians

1993-1996 Member, Program Committee, American Society of Transplant Physicians

1993-1996 Member, Scientific Advisory Board, United Network of Organ Sharing (UNOS)

1994-1998 Member, American Society of Hypertension CME Committee

1994-1998 Member, Physicians Manpower and Training Committee,

American Society of Transplant Physicians

1998-present Member, Editorial Board of American Journal of Kidney Diseases

2004-present Journal of Clinical Hypertension, Hypertension, Transplantation, and many others

2004-2008 Associate Editor, American Journal of Kidney Diseases

2004-present Section Editor Current Hypertension Reports

2004-present Section Editor, Current Opinion of Hypertension and Nephrology

2009-present Associate Editor, Clinical Nephrology

2010-present Associate Editor, American Journal of Nephrology


HONORS, AWARDS
1974 Phi Beta Kappa

1982 National Kidney Foundation Fellowship Award

1984 Traveling Fellowship Award, IX International Congress of Nephrology

1986 Traveling Fellowship Award, XI International Congress of the Transplantation Society

1987 Traveling Fellowship Award, X International Congress of Nephrology

1991 Volunteer Service Award, National Kidney Foundation

1994 Alpha Omega Alpha

1998 Distinguished Research Award, International Society of Hypertension in Blacks



COMMITTEE AND SERVICE ACTIVITIES
1983-1984 Housestaff Selection Committee

1983-1988 Member, Scientific Advisory Committee of Dr. John Warren's Program Project Entitled: "Complications of Long-Term Urinary Catheters in the Aged."

1986-present Housestaff Selection Committee

1984-1989 Department of Medicine Education Committee

1984-1986 Faculty Practice Offices Operations Committee

1984-1989 Task Force for Peer Review of Sophomore Pathology Medical School

1984,1985,1993 Judge, Medical School Research Day

1988-Present Student Appeals Committee

1985-1989 Clinical Years Curriculum Committee, Advisor for Senior Medical Students

1985-1989 Member, Baltimore Physicians for Social Responsibility

1986-present Chairman, Fund-Raising/Committee, National Kidney Foundation-Maryland

1986-present Department of Medicine Research Committee

1986-present Department of Medicine Benefits Committee

1987-present Board of Trustees, National Kidney Foundation - Maryland

1987-1990 Maryland Organ Procurement Center, Medical Advisory Board

1987-present Medical Advisory Board, National Kidney Foundation of Maryland

1987-present Reviewer of manuscripts for: Transplantation, American Journal of Kidney Diseases, Chest, New York State, Journal of Medicine, American Journal of Hypertension, Journal of Human Hypertension, Life Sciences, Journal of the American Society of Nephrology, Archives of Internal Medicine, American Journal of Cardiology, Kidney International, Hypertension

1988-1990 Board of Directors, Maryland Organ Procurement Center

1991-present Medical Advisory Board, Transplant Resource Center

1992- Member, Selection and Program Committee, Short-Term Research Training Program for Minority Undergraduate Students

1992- Preceptor, Short-Term Research Training Program for Minority Undergraduate Students

1993- Preceptor, Short-Term Research Training Program for Medical Students

Maryland State Advisory Council on HBP and Related Cardiovascular Risk Factors

1996-2000 Cardiorenal Study Section, NHLBI, National Institutes of Health

1997-present NIDDK Special Grants Review Committee, National Institutes of Health, R21,R33

2002-present NIDDK Grants Review Committee for Organ Transplantation

2007-presnet Grant Review Committee, VA Merit Review, Nephrology

TEACHING ACTIVITIES
1983-present 4-6 months attending transplant service

1-2 months attending consultative service

1983-present 1-2 months attending medical service

1983-84, 1987-91 Sophomore physical diagnosis

1983-present Multiple didactic talks to medical housestaff, shock-trauma, second, third and fourth year medical students, pharmacology department, clinical chemistry department. Lecturer of sophomore medical school nephrology course.

1986-92 Preceptor, Medical Clerkship of third year Medical Students



RESEARCH GRANTS AND AWARDS

Peer Review Grants
1984 American Red Cross, $20,325. "Evaluation of HLA-typed apheresis byproducts as alloenhancing agents in prospective renal transplant recipients." Principal Investigator.

1984 Bressler Research Fund, $3,000. "Evaluation of HLA-typed apheresis byproducts as alloenhancing agents". Principal Investigator.

1985 American Red Cross, $20,325. "Evaluation of HLA-typed apheresis byproducts as alloenhancing in prospective renal transplant recipients." Principal Investigator.

1987 Designated Research Initiative Funds, State of Maryland, $8,500. "The role of calcium in lymphocyte activation and function." Principal Investigator.

1987 National Kidney Foundation of Maryland, $4,500. "Additive effects of calcium channel blockers and cyclosporine on lymphocyte function." Principal Investigator.

1988 National Kidney Foundation of Maryland, $2500. "Additive effects of calcium channel blockers and cyclosporine on lymphocyte activation and function. Principal Investigator

1989 National Kidney Foundation of Maryland, $2500. "Additive effects of calcium channel blockers, prostaglandin metabolites and cyclosporine on lymphocyte activation and function."

Principal Investigator.

1990 National Kidney Foundation of Maryland, $2500. "Additive effects of calcium channel blockers, prostaglandin metabolites and cyclosporine on lymphocyte activation and function."

Principal Investigator.

1991 National Kidney Foundation of Maryland, $2500. "Additive effects of calcium channel blockers, prostaglandin metabolites and cyclosporine on lymphocyte activation and function."

Principal Investigator.

1992 National Kidney Foundation of Maryland, $2500. "Effects of calcium channel blockers of potassium channel blockers on lymphocyte activation and function." Principal Investigator.

1994 American Heart Association Grant-In-Aid, $44,000. "Exercise, Insulin and Sodium in Black Hypertensives." Principal Investigator.

1994 SERCA Award, $418,652. "Insulin action, sodium and exercise in the hypertension of Aging."

Co-Investigator.

2001 NIDDK 1U01DK61022-01(NIH) – Appel (PI) $1,639,923 9/28/2001 – 8/31/2008

Johns Hopkins Medical Institutions, Chronic Renal Insufficiency Cohort Study, Site Co-Investigator

The main goal of this project is to identify risk for factors associated with accelerated loss of renal function in patients with chronic renal insufficiency and to identify risk factors for cardiovascular disease associated with this condition.

2002 NHLBI HL67031-01A(NIH) B. Howard (PI) $211,546 4/1/2002 – 3/31/2008

Medstar Research Institute, Stop Atherosclerosis in Natives Diabetes Study (SANDS). This project is an interventional trial with lower levels of blood pressure and LDL-cholesterol reduction in Native Americans with type II diabetes and microalbuminuria. Outcome is based on carotid intimal plaque thickening. Site Principal Investigator.

2002 NHLBI UO1HL72515(NIH) Shuldiner (PI) $197,547 9/30/2002 – 9/29/2006

University of Maryland School of Medicine, Genome-Wide Search for CVD Gene Environment Interaction. The major goal of this project is to identify genes that interact with the environment in shaping the risk of cardiovascular disease. Site Co-Investigator

2002 NIDDK UO1 DK61700-01(NIH) Bostom (PI) $140,000 2/12/2002 – 1/31/2007

Lifespan, Rhode Island Hospital, Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT), Site Principal Investigator.

2005 R01/DK066013 Kasiske (PI) $228,519 9/15/2005-5/31/2012

University of Minnesota, Live Unrelated Kidney Donor and Sibling Follow-up Study. To investigate

biomeasures of cardiovascular risk in kidney donors. Site Principal Investigator .

2007 NIDDK UO2 DK61700-06 (NIH) Bostom (PI) $535,175 2/1/2007 – 1/31/2012

Lifespan, Rhode Island Hospital, Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT), Site Principal Investigator.

2007 No project number (Wilson) $50,000 7/1/2007-6/30/2008

University of Maryland Statewide Health Network Other Tobacco Related Diseases Research

The major goal of this project is to understand the effects of smoking on the graft function and explore the success of effectiveness of the smoking cessation in these patients with multiple co-morbidities. Role: PI

2008 NIDDK R21 AG033791 Mullins(PI) $200,00 11/2008-10/2010

Response to Medicare Reimbursement Policy Change by Minority and all ESRD patients, with regard

to access to renal transplantation.

2010 0468E5-4544 Weir $3,152,993 1/1/2010 – 3/30/2014

Spare the Nephron (STN) Continuation of Yearly Follow-up for another three years (a total of five-year study period). The plan is to evaluate change in measured GFR over time.

Principal Investigator

2010 R01 PA07-070 Fink $1,025,000 7/1/2010 – 6/30/2015

Does under-recognition of kidney disease affect patient safety?

The major goal of this study is to test the hypothesis that patients with chronic kidney disease (CKD) have a high frequency of both general and disease-specific safety events that account for a significant proportion of their adverse outcomes. An intervention (structural measure) that increases the recognition of CKD will reduce the occurrence of disease-specific unsafe practices and errors (process measures), and in turn, reduce the incidence of disease-specific adverse events (outcome measures).

2010 100255 Weir $148,504 4/26/2010 – 5/25/2013

A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients. The major goal of this study is to better understand the evolution of HPT (Hyperparathyroidism) in people during the first 12 months after receiving a kidney transplant.

Principal Investigator
RESEARCH GRANTS AND AWARDS

Industry
1984 Marion Laboratories, $90,000. "Comparison study of Diltiazem vs Atenolol in the treatment of mild to moderate hypertension." Co-Investigator.

1984 Miles Laboratories, $8,000. "Pharmacokinetic study of the renal excretion of Ciprofloxacin in patients with impaired renal function." Co-Investigator.

1985 Upjohn Co., $32,400. "The effects of topical Minoxidil in untreated hypertensives." Co-Investigator.

1985 Ayerst Laboratories. $55,728. "Hydrochlorothiazide dose finding study with Inderal LA." Co-Investigator.

1985 Syntex Laboratories. $60,000. "Nicardipine vs Propranolol in Mild to Moderate Hypertension."

Co-Investigator.

1986 American Cyanamid, Lederle Laboratories. $63,365.76. "Safety and Dose-Finding study of Nilvadipine in Hypertension." Principal Investigator.

1986 Merck, Sharp & Dohme. $18,000. "Vasotec-therapy in Mild to Moderate Hypertension."

Co-Investigator.

1986 Miles Laboratories, $6,000. "Pharmacokinetic Study of the renal excretion of intravenous ciprofloxacin in patients with impaired renal function." Co-Investigator.

1986 Syntex Laboratories, $48,211.20. "Nicardipine vs Captopril for Hypertension in the Elderly."

Co-Investigator.

1986 Marion Laboratories, $77,544. "A comparative Study of Urapidil vs Placebo in Mild to Moderate Hypertension." Principal Investigator.

1986 Merck, Sharp & Dohme. $63,936. "Comparison of the antihypertensive efficacy and tolerability of Vasotec and Hydrochlorothiazide and their Effects on Serum Lipids in Patients with Mild Uncomplicated Essential Hypertension." Principal Investigator.

1986 CIBA-GEIGY, $72,000. "CGS 13080: Thromboxane Synthetase Inhibition Effect on Renal Function and Blood Pressure." Principal Investigator.

1987 E.R. Squibb & Sons, Co., $33,000. "Capozide vs Tenoretic in Mild to Moderate Hypertension."

Principal Investigator.

1987 Pfizer Pharmaceuticals, $58,980. "Oral Nifedipine vs IV Labetalol in Hypertensive Urgencies." Co-investigator.

1987 Abbott Laboratories, $39,366. "Terazosin vs Propranolol in Elderly Hypertensives. " Co-principal Investigator.

1987 Searle Laboratories, $48,000. "Calan vs Tenormin vs Capoten in Black Hypertensives."

Co-principal Investigator.

1987 Dupont Critical Care, $70,000. "IV Nicardipine in hypertensive urgencies." Co-investigator.

1987 American Cyanamid Company, $72,072.00. "Efficacy of Nilvadipine in Hypertension." Principal Investigator.

1987 Merck, Sharpe & Dohme, $100,200. "Vasotec vs. Verapamil SR in Hypertension." Principal Investigator.

1987 A.H. Robins, $133,200. "Bopindolol in black hypertensives." Co-Principal Investigator.

1987 Marion Laboratories, $38,400. "Diltiazem SR vs HCTZ in Hypertension." Principal Investigator.

1987 Searle Laboratories $24,000. Unrestricted Educational Grant.

1988 Searle Laboratories $40,000. Unrestricted Education Grant.

1988 E.R. Squibb & Sons, $46,476.00. "Effect of Zofenopril in Hypertension." Principal Investigator."

1988 Marion Laboratories, $72,560.00. "Effect of Antihypertensive Therapy on Quality of Life in Elderly Females." Principal Investigator.

1988 Marion Laboratories, $54,000.00. "Efficacy of Diltiazem/Captopril Combination in Hypertension."

Principal Investigator.

1988 Syntex Laboratories, $57,552.00. "Once Daily Dose of RS-10085 in Essential Hypertension." Co-Investigator.

1988 Syntex Laboratories, $66,009.00. "Comparison of Nicardipine and HCTZ in the Treatment of Hypertension in Blacks." Principal Investigator.

1988 Merck, Sharpe & Dohme, $122,000. "Lisinopril vs. verapamil SR in the treatment of older hypertensives."

Principal Investigator.

1988 Merck, Sharpe & Dohme, $40,000. "Lisinopril vs verapamil SR in the treatment of black hypertensives.” Principal Investigator.

1988 Sandoz Research Institute, $9,200. Educational Grant. Principal Investigator.

1988 Marion Laboratories, $52,416. "Dose evaluation of Diltiazem SR/HCTZ in combination vs single agents and placebo in the treatment of hypertension." Principal Investigator.

1989 Searle Laboratories, $85,536.00. "Open label study of cytotec in the prevention of NSAID-induced renal dysfunction in the elderly." Principal Investigator.

1989 1989 Marion Laboratories, $35,550.00. "Diltiazem QD dose response hypertension trial." Principal Investigator.

1989 1989 Sandoz Research Institute, $82,917.00. "A clinical study to determine the efficacy and safety of cyclosporine and its effect on renal function in patients with rheumatoid arthritis." Co-Investigator.

1989 1989 Hoffman-LaRoche, $61,200. "Efficacy of cilazapril and/or HCTZ in hypertension." Co-Principal Investigator.

1989 1989 Merck, Sharp & Dohme, $49,900. "Evaluation of Vaseretic in mild to moderate hypertension."

1989 Principal Investigator.

1989 1989 Merck, Sharp & Dohme, $79,200. "Vasotec vs Cardizem SR for treatment of hypertension."

1989 Principal Investigator.

1989 1989 Rorer Pharmaceuticals, $61,500. "Comparative study of Lozol as add-on therapy to Calan SR."

1989 Co-Principal Investigator.

1989 1989 Knoll Pharmaceuticals, Inc., $84,600. "The safety and efficacy of Trandolapril in black hypertensives." Principal Investigator.

1989 1989 CIBA-GEIGY, 61,296.00. "The safety and tolerability of CGS 12970 in renal allograft recipients."

1989 Principal Investigator.

1989 1989 American Cyanamid, $64,920. "Randomized double-blind comparative study of

1989 bisoprolol in combination with HCTZ." Principal Investigator.

1989 Burroughs Welcome Co., $190,000. Retrovir in the treatment of HIV-infected patients in renal failure."

Co-Investigator.

1989 Parke-Davis, $204,000. "Evaluation of once vs twice daily dosing of Quinapril on renal function in patients with congestive heart failure." Co-Principal Investigator.

1990 Marion Laboratories, Inc. $68,500. "Dose response characteristics to TA-3090 in hypertensives." Principal Investigator.

1990 Glaxo, Inc. $104,300. "Isradipine vs HCTZ in the regression of left ventricular hypertrophy." Co-Principal Investigator.

1990 Glaxo, Inc. $156,000. "Impact of salt sensitivity on the effects of isradipine on blood pressure and renal hemodynamics. Principal Investigator.

1990 ICI Pharma. $31,200. "Lisinopril vs diltiazem SR in the treatment of moderate to severe hypertension." Principal Investigator.

1990 Bristol Myers Squibb, Inc. $68,900. "A comparison of fosinopril and verapamil SR on blood pressure and protein excretion in hypertensive patients with Type II diabetes mellitus." Principal Investigator.

1990 Knoll Pharmaceuticals, $58,000. "Open-label study of the long-term safety of oral trandolapril therapy in patients with mild to moderate essential hypertension." Principal Investigator.

1990 Roerig, $203,100. "A multicenter evaluation of the efficacy and side effect profile of doxazosin vs enalapril as initial antihypertensive therapy in patients with mild-to-moderate primary hypertension.” Principal Investigator.

1990 Hoffman-LaRoche, $32,100. "Multicenter, placebo controlled study evaluating the antihypertensive effect and safety of the cilazapril/hydrochlorothiazide combination. Principal Investigator.

1990 Knoll Pharmaceuticals, $60,500. "Double-blind, randomized, placebo-

controlled, factorial study to evaluate the safety and efficacy of oral trandolapril combination with verapamil." Principal Investigator.

1990 Merck, Sharpe & Dohme, $201,600. "Comparison of the efficacy and tolerability of lisinopril and extended-release nifedipine in mild to moderate uncomplicated essential hypertension."

Principal Investigator

1991 Lederle Laboratories, $26,200. "Isolated systolic hypertension in the elderly: a randomized, double- blind, placebo controlled trial of once-a-day Verelan verapamil 120 mg and 240 mg capsules in the treatment of isolated systolic hypertension in patients age 60 years and older." Principal Investigator

1991 ICI Pharma, $62,300. "Controlled clinical trial comparing Zestoretic 10-12.5 and Zestoretic 10-25 (lisinopril/hydrochlorothiazide) to each of the monocomponents and placebo in the treatment of mild to moderate essential hypertension." Principal Investigator.

1991 Knoll Pharmaceuticals, $55,200. "Open-label study of the long-term safety of oral trandolapril in combination with verapamil." Principal Investigator.

1991 Knoll Pharmaceuticals, $59,600. "Double-blind, randomized, placebo-controlled, five-way parallel dose-ranging study to evaluate the safety and efficacy of oral trandolapril therapy (4,8,12,16 mg/day) in black patients with mild to moderate essential hypertension." Principal Investigator.

1991 Knoll Pharmaceuticals, $56,700. "Evaluation of the safety and efficacy of oral trandolapril in

combination with verapamil (Isoptin SR) in patients with severe essential hypertension.

Principal Investigator.

1991 Marion Merrell Dow, $19,200. "Assessment of the safety and efficacy of diltiazem QD in patients whose hypertension is controlled by Cardizem SR. Principal Investigator.

1991 CIBA-GEIGY, $50,600. "A randomized, double-blind, placebo controlled, parallel-group comparison of monotherapy and combined therapy of benazepril 5 mg once daily and amlodipine 2.5 mg once daily for the treatment of patients with essential hypertension. Co-Principal Investigator.

1992 Merck, Sharp & Dohme, $12,000. "Efficacy and tolerability of extended release felodipine in adult patients with mild to moderate uncomplicated hypertension." Principal Investigator.

1992 CIBA Geigy, $47,712. "A randomized, double-blind, placebo controlled, parallel-group comparison of monotherapy and combined therapy of benazepril 20 mg once daily and amlodipine 5 mg once daily in black patients with essential hypertension." Co-Principal Investigator.

1992 Warner Lambert Company, $167,100. "The safety and efficacy of once daily quinapril for the treatment of mild, uncomplicated hypertension. Principal Investigator."

1992 R.W. Johnson Pharmaceutical Research Institute, $57,400. "A phase II double-blind titration comparison of perindopril erbumine and enalapril maleate in patients with mild to moderate hypertension." Principal Investigator.

1992 Merck, Sharpe Dohme, $12,000. "Efficacy and tolerability of simvastatin in the treatment of primary hypercholesterolemia." Principal Investigator

1992 Marion Merrell Dow, $22,700. "A comparative trial of the safety and efficacy of Cardizem CD and felodipine in elderly hypertensive patients." Principal Investigator.

1992 Hoechst-Roussel Pharmaceuticals, Inc. $135,000. "The impact of ramipril and nifedipine gits and high and low sodium intake on blood pressure, proteinuria, and renal hemodynamics in black hypertensives with renal dysfunction." Principal Investigator.

1992 Wyeth-Ayerst Laboratories, $42,000. "A multicenter, randomized, double-blind, placebo-controlled study to determine the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with mild to moderate hypertension controlled by verelan." Principal Investigator.

1992 Hoffman-LaRoche, Inc, $33,912. "A comparison of RO 40-5967 versus Diltiazem CD and placebo for the treatment of essential hypertension.” Principal Investigator

1992 Bristol Myers Squibb U.S. Pharmaceutical Division, $25,416. "A double- blind, randomized trial comparing once daily combination Captopril plus Hydrochlorothiazide versus Nifedipine GITS in black patients with mild-to-moderate essential hypertension." Co-Investigator.

1993 Sandoz Pharmaceuticals Corporation, $20,300. "Impact of Isradipine and sodium intake on blood pressure proteinuria and renal hemodynamics in hypertensive renal transplant patients." Principal Investigator

1993 Parke-Davis, $16,800. Impact of Quinapril and high and low sodium intake on blood pressure, proteinuria, and renal hemodynamics in hypertensive renal transplant recipients." Principal Investigator

1993 Merck & Co., Inc, $21,200. "A multicenter, prospective, double-blind, randomized, parallel, comparison study of the quality of life and the efficacy and tolerability of 40 mg of Lovastatin versus 40 mg Pravastatin in male patients with primary hypercholesterolemia (types IIa and IIb)." Principal Investigator.

1993 Merck & Co., $24,000. "A multicountry, double-blind study to evaluate the quality of life of

hypercholesterolemic patients treated with simvastatin or pravastatin." Principal Investigator.

1993 Advanced Metabolic Systems, $193,136. "Anti-nephropathic effects of chronic intermittent intravenous insulin therapy in type I diabetics." Principal Investigator.

1993 Sandoz Pharmaceuticals, $92,280. "Dietary salt and blood pressure control with isradipine or enalapril." Principal Investigator.

1993 Lederle Laboratories, $58,320. "Efficacy and safety of verelan vs cardizem in hypertension."

Principal Investigator.

1993 Bristol-Myers Squibb, $46,368. "A multicenter 8-week study of the antihypertensive activity and safety of BMS-186295/SR 47436 in mild to moderate hypertensives. Principal Investigator.

1993 Sankyo U.S.A. Corporation, $36,800. Efficacy and safety of temocapril alone and in combination with hydrochlorothiazide. Principal Investigator.

1993 Hoffmann LaRoche, Inc., #76,800. "Long term safety and efficacy of Ro-40-5967 in hypertension. Principal Investigator.

1993 Marion Merrell Dow Inc., $22,410. "A comparative trial of the safety and efficacy of cardizem CD and amlodipine in older patients." Principal Investigator.

1993 Knoll Pharmaceuticals, $108,432. "Antihypertensive/antiproteinuric effects of verapamil and trandolapril." Principal Investigator.

1993 Bristol-Myers Squibb, $75,408. "A multicenter 8-week study of the antihypertensive activity and safety of BMS-186295 in mild to moderate hypertension." Principal Investigator.

1994 Bristol-Myers Squibb, $45,548. "Dose-ranging study II: A multicenter trial of the antihypertensive activity and safety of 100, 200, and 300 mg SR 47436 (BMS-186295) in mild-to-moderate hypertension." Principal Investigator.

1994 Marion Merrell Dow Inc., $57,960. "Diltiazem ER/Enalapril combination therapy in hypertensive patients not responding adequately to diltiazem CD (Cardizem CD) monotherapy." Principal Investigator.

1994 ZENECA, $35,616. "A placebo-controlled study assessing the treatment effects of lisinopril versus hydrochlorothiazide (HCTZ) in obese patients with hypertension - Trophy 1262US/0004." Principal Investigator

1994 Wyeth-Ayerst, $56,640. "A randomized, double-blind, placebo-controlled, multicenter, dose titration trial of ANA-756 in patients with essential hypertension." Principal Investigator

1994 CIBA-GEIGY, $47,910. "Randomized, double-blind, placebo-controlled, parallel-group trial comparing valsartan 20 mg, 80 mg, 160 mg, and 320 mg to placebo in patients with essential hypertension followed by an open-label extension of 52 weeks duration." Principal Investigator.

1994 Parke-Davis, $47,140. "A double-blind, randomized, comparative study to examine the single agent efficacy and tolerability of Accupril (quinapril), versus placebo for the treatment of mild to moderate hypertension in black and white subjects. (Protocol 906-379). Accupril in minorities (AIM) project." Co-Investigator.

1995 Bristol-Meyers Squibb/Medex, $55,200. "Metformin hydrochloride vs. placebo in non-insulin dependent diabetics." Co-Investigator

1995 Merck, $13,980. "COZAAR and HYZAAR vs. Procardia XL in patients with hypertension." Principal Investigator.

1995 Merck, 11,050. "COZAAR and HYZAAR vs. Procardia XL in elderly patients with hypertension." Principal Investigator.

1995 Lederle/Medex,$40,320. "Verelan vs Norvasc in Women with Hypertension." Principal Investigator.

1995 Wyeth-Ayerst, $75,650. "A randomized, double-blind, placebo-controlled, multicenter, dose titration trial of ANA-756 in patients with essential hypertension." Principal Investigator.

1995 Bristol-Myers Squibb, $14,730. Antihypertensive activity and Safety of Irbesartan in patients with hypertension. Principal Investigator.

1995 Medex, $16.667. Multicenter Trial of HCTZ (12.5mg). Principal Investigator.

1995 Bristol-Myers Squibb, $83,333. Phase II study of the treatment of Acute Renal Graft Rejection. Principal Investigator.

1995 Wyeth Ayerst, Direct $114,812/Indirect $28,628. ANA756 (304) vs Atenolol in Hypertensives. Principal Investigator

1995 Merck & Co, Direct $15,401/Indirect $3,715. Simvastatin and Fluvastatin(Zocor). Principal Investigator.

1995 Merck & Co, Direct $6,200/Indirect $1,550. Losartan effectiveness and tolerability (LET). Principal Investigator.

1995 Bristol-Myers Squibb, Direct $28,280/Indirect $7,070. Irbesartan in Hypertensives-050. Principal Investigator.

1996 Bristol-Myers Squibb, Direct $28,750/Indirect $5,750.Dual Metalloprotease Inhibitor, BMS186716. Principal Investigator.

1996 Forest Laboratories, Inc. Direct $27,083/Indirect $5,167. Calcium Channel Blockers in reducing Proteinuria. Principal Investigator.

1996 Merck & Co, Direct $33,178/ Indirect $8,294. Losartan Intervention for Endpoint Reduction (LIFE). Principal Investigator.

1996 Bristol-Myers Squibb, Direct $57,760/ Indirect $14,440. Irbesartan in Type II Diabetics with Nephropathy. Principal Investigator.

1996 Merck & Co, Direct $71,250/Indirect $14,250. Losartan in patients with Diabetes Mellitus.

Principal Investigator.

1996 Bristol-Myers Squibb, Direct $43,639/ Indirect $10,909. Irbesartan in Mild to Moderate

Hypertensives. Principal Investigator.

1996 Astra Merck, Direct $55,373 Indirect $13,843. Fixed Combination of Candesartan and HCTZ. Principal Investigator.

1996 Bristol-Myers Squibb, Direct $29,167 Indirect $5,833. Multicenter, randomized, forced titration trial antihypertensive efficacy and safety Irbesartan compared with losartan for treatment of mild to moderate hypertensives-088. Principal Investigator.

1996 Merck & Co, Direct $45,625 Indirect $9,125. Study of the effects of the non-steroidal anti-inflammatory drug indomethacin on the anti-hypertensive response to losartan versus captopril in essential hypertension. Principal Investigator.

1996 Searle, Direct $24,000 Indirect $6,000. Revised clinical protocol for controlled onset verapamil investigation of cardiovascular endpoints. Principal Investigator.

1996 Merck & Co, Direct $51,067 Indirect $10,213. African-American ECHO substudy for LIIFE. Principal Investigator.

1997 Roche, Direct $181,940 Indirect $36,388. Cooperative Clinical Trials in Adult Transplantation (CCTAT) Hoffman LaRoche steroid sparing trial. Principal Investigator.

1997 Roche, Direct $150,000 Indirect $30,000. MMF rescue therapy in chronic rejection. Principal Investigator.

1997 Merck & Co, Direct $29,167 Indirect $5,833. The influence of losartan and enalapril on blood pressure and proteinuria in hypertensives with normal renal function. Principal Investigator.

1997 Merck & Co, Direct $29,167 Indirect $5,833. The influence of dietary salt and losartan therapy on blood pressure and proteinuria in hypertensives with normal renal function. Principal Investigator.

1997 Novartis, Direct $14,350 Indirect $2,870. A randomized, double blind, placebo-controlled, forced-titration parallel safety efficacy of Lotrel 5/20 mg to Lotrel 10/20 mg once daily in patients with hypertension. Co-principal Investigator.

1997 ISHIB/Bayer, Direct $33,340 Indirect $6,660. Calcium antagonists in Blacks. Co-principal Investigator.

1997 Hoffman-La Roche, Direct $86,792 Indirect $17,358. Immunosuppression Withdrawal in Stable Renal Allograft Recipients Treated with Triple Therapy. Principal Investigator.

1997 Covance, Direct $45,500 Indirect $9,100. Placebo Controlled Study of Moxonidine in Stage 1 and Stage 2 Hypertension. Co-principal Investigator.

1997 Novartis, Direct $117,000 Indirect $23,400. Comparative Effects of Diuretics and Ace Inhibitors to Alleviate Ankle Edema Due to Calcium Antagonist. Principal Investigator.

1997 Novartis, Direct $106,425 Indirect $21,285. The influence of dietary salt and valsartan therapy on blood pressure and proteinuria in hypertensive African Americans. Principal Investigator.

1998 Astra Merck, Direct $55,090 Indirect $11,018. The ABC Study of Hypertension: Protocol 140."

Co-principal Investigator.

1998 Smith Kline Beecham, Direct $31,967 Indirect $6,393. A Double Blind Efficacy and Safety Study of Baycol (cerivastatin) & Pravacol (pravastatin) in treatment of hypercholesterolemia. Co-principal Investigator.

1998 Merck & Co., Direct $31,302 Indirect $6,260. Losartan in African American Patients with Mild-to-Moderate Hypertension. Co-principal Investigator.

1998 Novartis, Direct $65,494 Indirect $13,099. VALUE (Diovan Antihypertensive Long-term Use Evaluation). Co-principal Investigator.

1998 Covance, Direct $36,000 Indirect $7,200. Open Label Study of Neoral as Primary Immunosuppressant Therapy in Transplant Patients Who are Unable to Maintain Immunosuppression. Co-principal Investigator.

1998 Merck & Co., Direct $11667 Indirect $2,333. A Triple-Blind, Randomized, Parallel, Efficacy Study of Losartan Versus Irbesartan in Patients With Mild to Moderate Essential Hyperten. Coz442. Principal Investigator.

1998 Smith Kline Beecham, Direct $71,250 Indirect $14,250. Forced Titration Study of Teveten (Eprosartan mesylate; SK&F 108566-J) at Doses of 600 mg and 1200 mg Once Daily in African Americans. Principal Investigator.

1998 Bristol-Myers Squibb, Direct $29,167 Indirect $5,833. A Study of the antiproteinuric Effects of Omapatrilat and Amlodipine in Type II Diabetic with Hypertension and Microalbuminuria. Principal Investigator.

1999 Merck-Sharpe and Dohme, Direct $26,220. Losartan and enalapril alone in combination on blood pressure and proteinuria in hypertensive-normal renal function. Principal Investigator.

1999 Fujisawa Healthcare, Direct $100,000. Prograf as secondary intervention in chronic allograft nephropathy. Prinicipal Investigator.

1999 Hoechst Marion Roussel, Direct$23,760. Dose response with intravenous HMR396 in Anemic Patients. Principal Investigator.

1999 Astra Pharmaceuticals Products, $94,500. A comparison of angiotensin receptor blockade vs calcium channel blockade on allograft nephropathy. Principal Investigator.

1999 Novartis. Tolerability of ERL080A.

2000 Fujisawa, 100,000 Direct, 20,000 Indirect. Prograf vs cyclosporine in patients with renal failure. Principal Investigator

2000 Hoffmann-LaRoche Company, 129,167 Direct, 25,8333 Indirect. Treatment for chronic allograft nephropathy. Principal Investigator

2000 Hoffmann-LaRoche Company, 86,500 Direct, 17,300 Indirect. Immunosuppression in renal allograft triple therapy. Principal Investigator

2000 Merck, Sharp and Dohme, 10.662 Direct, 2,133 Indirect. Losartan intervention for endpoint reduction in hypertension. Principal Investigator

2000 Merck, Sharp and Dohme, 9,510 Direct, 1,902 Indirect. Losartan in patients with non-insulin dependent diabetes.

2001 Biovail Laboratories. Diltiazem HCL Extended Release Capsules.

2001 Novartis. Enalapril in Treatment of Hypertension in Type 2 Diabetics.

2001 Novartis Pharmaceuticals, University of Maryland School of Medicine, The National Living Renal Transplant Registry, Co-Medical Director. 7/1/2001 – 6/30/2003. The major goal of this project is to conduct a multi-center Web-based registry to track the longitudinal outcome of living renal transplant recipients who are treated with or without basiliximab (Simulect).

1996-2000 Bristol-Myers Squibb, IDNT Study

1996-2000 Merck Sharp & Dohme, RENAAL Study

1996-2001 Novartis Pharmaceuticals VALUE Study

1996-2000 Merck Sharp & Dohme, LIFE Study



2006-2009 Roche Pharmaceuticals, STN Trial
  1   2   3   4   5   6   7


The database is protected by copyright ©dentisty.org 2016
send message

    Main page